Clinical efficacy of XXXX in eradication of @entity1534 .

@entity1 @entity10189 @entity115 @entity1066 @entity10042 @entity1534 @entity2275
A randomized, single-blind study was designed to assess the effect of @entity10042 alone and @entity10042 plus @entity115 on the healing and eradication rates in @entity1534 -associated @entity10189 . Seventy-nine @entity1 with @entity2275 and 54 @entity1 with duodenal @entity1066 were randomly assigned to two treatment groups. Group 1 received @entity10042 30 mg daily for 8 weeks for @entity2275 or 6 weeks for duodenal @entity1066 . Group 2 received the group 1 regimen plus @entity115 2 g daily for 2 weeks. Healing rates at 8 weeks for the @entity2275 @entity1 were 92 and 84% in groups 1 and 2, respectively (p = not significant). Healing rates at 6 weeks for duodenal @entity1066 were 96% in group 1 and 100% in group 2 (p = not significant). The eradication rates of @entity1534 for @entity2275 @entity1 were 21 and 54% in groups 1 and 2, respectively (p < 0.05). The @entity1534 eradication rates for duodenal @entity1066 @entity1 were 5 and 73% in groups 1 and 2, respectively (p < 0.001). The @entity1534 eradication rates in group 2 were significantly higher than in group 1. @entity10042 was effective for eradicating @entity1534 in this study.
